Polycystic liver disease is the most common extra-renal manifestation of autosomal dominant polycystic kidney disease (ADPKD). There is need for robust long-term evidence for the volume-reducing effect of somatostatin analogues.
Related news items
Human pluripotent stem cell-derived kidney organoids for personalized congenital and idiopathic nephrotic syndrome modeling11 May 2022
Bart Smeets, Jitske Jansen and collegues, theme Renal disorders published this article in the Human Development.read more
ERC Starting Grant awarded to Jeroen de Baaij17 March 2022
Jeroen de Baaij, kidney researcher the Radboudumc, receives an ERC Starting Grant worth 1.5 million euros. He will use this grant to improve the diagnosis and treatment of severe magnesium deficiencies, which can lead to epileptic seizures and muscle cramps.read more